Global Short Bowel Syndrome Market Report By Product (Glucagon-like Peptide (GLP2), Growth Harmone, Glutamine, Others), By Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2023-2032
The global demand for Short Bowel Syndrome Market is presumed to reach the market size of nearly USD 5522.45 MN by 2030 from USD 841.12 MN in 2022 with a CAGR of 26.52% under the study period 2023 - 2030.
Short Bowel Syndrome or SBS is a condition in which the small intestine or its portion is surgically removed or is not functioning properly, causing malnutrition and diarrhoea. The small intestine is the body part responsible for absorbing nutrients from food, and when a portion of it is missing, the body is unable to absorb enough nutrients to meet its needs. SBS can result due to conditions including Crohn's disease, cancer, and injury to the small intestine. Symptoms of SBS may include malnutrition, diarrhoea, abdominal pain, and weight loss. In severe cases, patients may require intravenous nutrition (known as parenteral nutrition) to maintain their health.
The incidence of Short Bowel Syndrome is increasing due to factors such as the increasing prevalence of conditions that lead to bowel resection, such as Crohn's disease and cancer. This is driving the demand for SBS treatments. Development of new surgical techniques and the introduction of new drugs and devices are driving the growth of the SBS market. These advances are leading to better patient outcomes and improved quality of life for SBS patients. The growing awareness about Short Bowel Syndrome, both among healthcare professionals and the general public, is driving the demand for SBS treatments. This awareness is leading to earlier diagnosis and more effective treatment of SBS. Increased investment in SBS research, both by the government and private organizations, is driving the growth of the SBS market. This investment is leading to the development of new, more effective SBS treatments. There is a significant medical need which has not been met for effective treatments for SBS. This is driving the demand for new and improved SBS treatments and is expected to continue to drive the growth of the SBS market in the future.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of short bowel syndrome. The growth and trends of short bowel syndrome industry provide a holistic approach to this study.
This section of the short bowel syndrome market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
Glucagon-Like Peptide (GLP2)
This section covers the regional outlook, which accentuates current and future demand for the Short Bowel Syndrome market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Short Bowel Syndrome Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the short bowel syndrome market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc, Nutrinia Ltd., Hanmi Pharm Co Ltd, Pharmascience Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . SHORT BOWEL SYNDROME – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Product
3.7.2 Market Attractiveness Analysis By Distribution
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
6 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY PRODUCT
6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Glucagon-like Peptide (GLP2) Historic and Forecast Sales by Regions
6.5 Growth Harmone Historic and Forecast Sales by Regions
6.6 Glutamine Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions
7 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY DISTRIBUTION
7.1 Overview by Distribution
7.2 Historical and Forecast Data
7.3 Analysis by Distribution
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
Frequently Asked Questions (FAQs) about this Report
For the year 2022, the global market size for short bowel syndrome was valued at USD 841.12 Million.
The global short bowel syndrome market growth is estimated to be close to 26.52% between 2023 and 2030.
North America occupies the highest market share in the global short bowel syndrome market.
The global short bowel syndrome market is segmented by Product (Glucagon-like Peptide (GLP2), Growth Harmone, Glutamine, Others), by Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
The leading players in the global short bowel syndrome market are Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc, Nutrinia Ltd., Hanmi Pharm Co Ltd, Pharmascience Inc.